Source: Eur Respir J 2015; 46: 486-494
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Saini Gauri, Porte Joanne, Weinreb Paul H., Violette Shelia M., Wallace William A., McKeever Tricia M., Jenkins Gisli. alpha-v-beta-6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur Respir J 2015; 46: 486-494

Member's Comments

No comment yet.

Related content which might interest you: The prognostic role of matrix metalloproteinase-7 in scleroderma-associated interstitial lung disease Source: Eur Respir J, 58 (6) 2101560; 10.1183/13993003.01560-2021 Year: 2021 The analysis of prognostic factors in patients with interstitial lung diseases Source: International Congress 2015 – New insights into IIPs Year: 2015 Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020 Year: 2020 KL-6 as a potential therapeutic biomarker in fibrosing interstitial lung diseases Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016 Year: 2017 Prognostic factors of interstitial lung disease (ILD) Source: Eur Respir J 2001; 18: Suppl. 33, 527s Year: 2001 Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis Source: Eur Respir J 2016; 48: 1612-1621 Year: 2016 The prognostic value of extended lung function characterization in COPD Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers Year: 2020 Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 327s Year: 2006 CXCL12 as a potential disease marker for pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker? Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008 Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease? Source: International Congress 2016 – Connective tissue disorders Year: 2016 Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019 Osteopontin and interleukin-6 as biomarkers of interstitial lung disease Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020 Time in lung cancer diagnosis and its prognostic implication Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018 Predictive value of 18F-FDG PET/CT for chemotherapy-related acute exacerbation of interstitial lung disease in lung cancer patients with interstitial lung disease Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Markers of angiogenesis in serum are correlating with disease progress in lung cancer Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006